Phenazopyridine

Summary

Phenazopyridine (CHEMBL1242) is an approved small molecule (ATC G04BX06); indicated across 3 conditions.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G04BX06
• Indications: 3 conditions
• Clinical trials: 15
• Chemistry: 213.24 Da · C11H11N5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1242
Name	Phenazopyridine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4756
ATC	G04BX06
Molecular formula	C11H11N5
Molecular weight	213.24
InChIKey	QPFYXYFORQJZEC-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)N=NC2=C(N=C(C=C2)N)N

IUPAC name: 3-phenyldiazenylpyridine-2,6-diamine

Also known as: Fenazopiridina, NSC-145895, Phenazopyridine, SID104171363, PHENAZOPYRIDINE, PHENAZOPYRIDINE HYDROCHLORIDE, phenazopyridine

Parent form; salt/anhydrous children: CHEMBL1201022

Patent coverage: 1,589 distinct patent families (4,686 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 23 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 3A, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, D(1A) dopamine receptor, Thromboxane A2 receptor, Muscarinic acetylcholine receptor M1, D(2) dopamine receptor, Prostaglandin G/H synthase 1, Sodium-dependent noradrenaline transporter.

Bioactivity

ChEMBL activities: 14 potent at pChembl ≥ 5 of 24 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR2C	5.72	AC50	1908	nM	CHEMBL_ACT_25131641
OPRD1	5.54	AC50	2900	nM	CHEMBL_ACT_25153899
DRD3	5.51	AC50	3100	nM	CHEMBL_ACT_25193359
ADRA2B	5.5	AC50	3200	nM	CHEMBL_ACT_25143534
OPRK1	5.48	AC50	3300	nM	CHEMBL_ACT_25129274
DRD2	5.48	AC50	3300	nM	CHEMBL_ACT_25140160
HTR3A	5.48	AC50	3300	nM	CHEMBL_ACT_25148956
CHRM3	5.44	AC50	3600	nM	CHEMBL_ACT_25136528
ADRA2C	5.43	AC50	3700	nM	CHEMBL_ACT_25147704
SLC6A2	5.42	AC50	3850	nM	CHEMBL_ACT_25146009
CHRM1	5.39	AC50	4100	nM	CHEMBL_ACT_25135280
HRH1	5.35	AC50	4500	nM	CHEMBL_ACT_25212338
SLC6A3	5.33	AC50	4710	nM	CHEMBL_ACT_25124968
DRD1	5.03	AC50	9350	nM	CHEMBL_ACT_25115219

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4).

The 3 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
PHASE3	5
Not specified	5
PHASE4	4
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06577493	PHASE4	ACTIVE_NOT_RECRUITING	Effectiveness of Phenazopyridine for Pain Following Urodynamics
NCT03302936	PHASE4	COMPLETED	Assessing Pyridium for Post-Sling Urinary Retention
NCT03755089	PHASE4	UNKNOWN	Oral vs Intravesical Analgesia for Office Bladder Botox Injections
NCT06514430	PHASE4	WITHDRAWN	Prophylactic Analgesia for Bladder Botox Injections
NCT01064024	PHASE3	COMPLETED	Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo
NCT01650051	PHASE3	COMPLETED	Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI)
NCT01657448	PHASE3	COMPLETED	Efficacy Study of Methenamine + Methylthioninium Chloride vs Phenazopyridine for the Symptomatic Control of Dysuria
NCT02806713	PHASE3	COMPLETED	The Effect of Oral PhenazopyrIdine on Perioperative Voiding After Mid-urethral sliNg (EPIPhANy Study)
NCT03065075	PHASE3	COMPLETED	Effect of Phenazopyridine on Prolapse Surgery Voiding Trials
NCT02380573	PHASE2	COMPLETED	Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer’s Disease
NCT02424149	Not specified	COMPLETED	Phenazopyridine for Confirmation of Ureteral Patency
NCT02476448	Not specified	COMPLETED	Evaluation of Ureteral Jets on Cystoscopy
NCT02703558	Not specified	WITHDRAWN	Evaluation of Fluorescein Use During Cystoscopy
NCT02715648	Not specified	UNKNOWN	Using Phenazopyridine for In-office Cystoscopy
NCT02757417	Not specified	WITHDRAWN	Intravenous Sodium Fluorescein Versus Oral Phenazopyridine for Ureteral Patency

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol,	CPIC	G6PD

PharmGKB also curates 1 clinical and 3 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).